Relevant bibliographies by topics / Ovarian ablation

Contents

  1. Journal articles
  2. Books
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Ovarian ablation'

Author: Grafiati
Published: 4 June 2025
Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ovarian ablation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ovarian ablation"

1

Turner, Emily C., Jeremy Hughes, Helen Wilson, et al. "Conditional ablation of macrophages disrupts ovarian vasculature." REPRODUCTION 141, no. 6 (2011): 821–31. http://dx.doi.org/10.1530/rep-10-0327.

Full text
Abstract:
Macrophages are the most abundant immune cell within the ovary. Their dynamic distribution throughout the ovarian cycle and heterogenic array of functions suggest the involvement in various ovarian processes, but their functional role has yet to be fully established. The aim was to induce conditional macrophage ablation to elucidate the putative role of macrophages in maintaining the integrity of ovarian vasculature. Using the CD11b-diphtheria toxin receptor (DTR) mouse, in which expression of human DTR is under the control of the macrophage-specific promoter sequence CD11b, ovarian macrophages were specifically ablated in adult females by injections of diphtheria toxin (DT). CD11b-DTR mice were given DT treatment or vehicle and ovaries collected at 2, 8, 16, 24 and 48 h. Histochemical stains were employed to characterise morphological changes, immunohistochemistry for F4/80 to identify macrophages and the endothelial cell marker CD31 used to quantify vascular changes. In normal ovaries, macrophages were detected in corpora lutea and in the theca layer of healthy and atretic follicles. As macrophage ablation progressed, increasing amounts of ovarian haemorrhage were observed affecting both luteal and thecal tissue associated with significant endothelial cell depletion, increased erythrocyte accumulation and increased follicular atresia by 16 h. These events were followed by necrosis and profound structural damage. Changes were limited to the ovary, as DT treatment does not disrupt the vasculature of other tissues likely reflecting the unique cyclical nature of the ovarian vasculature and heterogeneity between macrophages within different tissues. These results show that macrophages play a critical role in maintaining ovarian vascular integrity.
APA, Harvard, Vancouver, ISO, and other styles
2

Deenarn, Pacharawan, Punsa Tobwor, Vanicha Vichai, et al. "Polychaete consumption increased prostaglandin biosynthesis in female Penaeus monodon." Reproduction 160, no. 6 (2020): 873–85. http://dx.doi.org/10.1530/rep-20-0217.

Full text
Abstract:
The polychaete Perinereis nuntia is preferred over commercial feed pellets for boosting ovarian maturation of the female black tiger shrimp Penaeus monodon. High levels of prostaglandins in polychaetes are believed to enhance shrimp ovarian development. However, the impact of polychaete feeding on shrimp prostaglandin biosynthesis and fatty acid regulatory pathways have yet to be investigated. As polychaetes contain higher levels of arachidonic acid (ARA), eicosapentaenoic acid (EPA), prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) than feed pellets, we examined the effects of polychaete feeding alone and in combination with eyestalk ablation on shrimp hepatopancreases and ovaries. Shrimp fed with polychaetes contained higher levels of EPA, PGE2 and PGF2α in hepatopancreases than those of pellet-fed shrimp. Similarly, higher levels of ARA and higher transcription levels of cyclooxygenase (COX) and prostaglandin F synthase (PGFS) were detected in ovaries of polychaete-fed shrimp compared to those of pellet-fed shrimp. The combination of polychaete-feeding and eyestalk ablation, commonly practiced to induce ovarian development, increased levels of ARA and EPA and transcription levels of COX in hepatopancreases and ovaries of polychaete-fed shrimp compared to those of pellet-fed shrimp. In ovaries, prostaglandin biosynthesis gene transcripts were induced by polychaete feeding while transcriptional levels of fatty acid regulatory genes were regulated by shrimp feed and eyestalk ablation. Our findings not only elucidate the effects of polychaete consumption on shrimp prostaglandin biosynthesis and fatty acid regulatory pathways during larvae production, but also suggests that high levels of dietary ARA, EPA and prostaglandins are essential during P. monodon ovarian development.
APA, Harvard, Vancouver, ISO, and other styles
3

Jagadish, Nirmala, Rukhsar Fatima, Aditi Sharma, et al. "Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma." Tumor Biology 40, no. 5 (2018): 101042831877365. http://dx.doi.org/10.1177/1010428318773652.

Full text
Abstract:
SPAG9 is a novel tumor associated antigen, expressed in variety of malignancies. However, its role in ovarian cancer remains unexplored. SPAG9 expression was validated in ovarian cancer cells by real time PCR and Western blot. SPAG9 involvement in cell cycle, DNA damage, apoptosis, paclitaxel sensitivity and epithelial- mesenchymal transition (EMT) was investigated employing RNA interference approach. Combinatorial effect of SPAG9 ablation and paclitaxel treatment was evaluated in in vitro. Quantitative PCR and Western blot analysis revealed SPAG9 expression in A10, SKOV-3 and Caov3 compared to normal ovarian epithelial cells. SPAG9 ablation resulted in reduced cellular proliferation, colony forming ability and enhanced cytotoxicity of chemotherapeutic agent paclitaxel. Effect of ablation of SPAG9 on cell cycle revealed S phase arrest and showed decreased expression of CDK1, CDK2, CDK4, CDK6, cyclin B1, cyclin D1, cyclin E and increased expression of tumor suppressor p21. Ablation of SPAG9 also resulted in increased apoptosis with increased expression of various pro- apoptotic molecules including BAD, BID, PUMA, caspase 3, caspase 7, caspase 8 and cytochrome C. Decreased expression of mesenchymal markers and increased expression of epithelial markers was found in SPAG9 ablated cells. Combinatorial effect of SPAG9 ablation and paclitaxel treatment was evaluated in in vitro assays which showed that ablation of SPAG9 resulted in increased paclitaxel sensitivity and caused enhanced cell death. In vivo ovarian cancer xenograft studies showed that ablation of SPAG9 resulted in significant reduction in tumor growth. Present study revealed therapeutic potential of SPAG9 in ovarian cancer.
APA, Harvard, Vancouver, ISO, and other styles
4

Jacobs, Ira A., C. K. Chang, and George Salti. "Hepatic Radio frequency Ablation of Metastatic Ovarian Granulosa Cell Tumors." American Surgeon 69, no. 5 (2003): 416–18. http://dx.doi.org/10.1177/000313480306900511.

Full text
Abstract:
Intrahepatic recurrences of a granulosa cell tumor of the ovary after primary resection has traditionally been considered a relative contraindication to surgical management. Improvements in ablative technologies such as radiofrequency ablation (RFA) offer the surgeon additional alternatives in the management of selected intrahepatic tumors. We present a case report of an intrahepatic recurrence of a metastatic ovarian granulosa cell tumor 6 months after primary resection. The patient received RFA of the intrahepatic lesions and the patient remains free of detectable disease 14 months later. A review of the literature is presented. This is the first known report of the use of RFA for intrahepatic recurrence of a metastatic ovarian granulosa cell tumor. In selected cases of metastatic ovarian granulosa cell tumors to the liver RFA may increase the percentage of patients considered surgically treatable.
APA, Harvard, Vancouver, ISO, and other styles
5

Ejlertsen, Bent, Henning T. Mouridsen, Maj-Britt Jensen, et al. "Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer." Journal of Clinical Oncology 24, no. 31 (2006): 4956–62. http://dx.doi.org/10.1200/jco.2005.05.1235.

Full text
Abstract:
Purpose To compare the efficacy of ovarian ablation versus chemotherapy in early breast cancer patients with hormone receptor–positive disease. Patients and Methods We conducted an open, randomized, multicenter trial including premenopausal breast cancer patients with hormone receptor–positive tumors and either axillary lymph node metastases or tumors with a size of 5 cm or more. Patients were randomly assigned to ovarian ablation by irradiation or to nine courses of chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) administered every 3 weeks. Results Between 1990 and May 1998, 762 patients were randomly assigned, and the present analysis is based on 358 first events. After a median follow-up time of 8.5 years, the unadjusted hazard ratio for disease-free survival in the ovarian ablation group compared with the CMF group was 0.99 (95% CI, 0.81 to 1.22). After a median follow-up time of 10.5 years, overall survival (OS) was similar in the two groups, with a hazard ratio of 1.11 (95% CI, 0.88 to 1.42) for the ovarian ablation group compared with the CMF group. Conclusion In this study, ablation of ovarian function in premenopausal women with hormone receptor–positive breast cancer had a similar effect to CMF on disease-free and OS. No significant interactions were demonstrated between treatment modality and hormone receptor content, age, or any of the well-known prognostic factors.
APA, Harvard, Vancouver, ISO, and other styles
6

Pais, Ana Sofia, Clara Flagothier, Linda Tebache, Teresa Almeida Santos, and Michelle Nisolle. "Impact of Surgical Management of Endometrioma on AMH Levels and Pregnancy Rates: A Review of Recent Literature." Journal of Clinical Medicine 10, no. 3 (2021): 414. http://dx.doi.org/10.3390/jcm10030414.

Full text
Abstract:
Ovarian endometrioma are found in up to 40% of women with endometriosis and 50% of infertile women. The best surgical approach for endometrioma and its impact on pregnancy rates is still controversial. Therefore, we conducted a literature review on surgical management of ovarian endometrioma and its impact on pregnancy rates and ovarian reserve, assessed by anti-Müllerian hormone (AMH) serum levels. Ovarian cystectomy is the preferred technique, as it is associated with lower recurrence and higher spontaneous pregnancy rate. However, ablative approaches and combined techniques are becoming more popular as ovarian reserve is less affected and there are slightly higher pregnancy rates. Preoperative AMH level might be useful to predict the occurrence of pregnancy. In conclusion, AMH should be included in the preoperative evaluation of reproductive aged women with endometriosis. The surgical options for ovarian endometrioma should be individualized. The endometrioma ablation procedure seems to be the most promising treatment.
APA, Harvard, Vancouver, ISO, and other styles
7

Manahan, Kelly J., and John P. Geisler. "Clinical effect of liver transaminase abnormalities after ablation of ovarian cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e17042-e17042. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17042.

Full text
Abstract:
e17042 Background: At initial presentation, patients with ovarian cancer often have disease involving the upper abdomen and specifically the liver (surface or parenchyma). The object of this study was to 1) see the difference in liver enzyme levels in women getting tumor ablation involving the liver compared to women getting tumor ablation not involving the liver and to 2) see if any differences had a readily noticeable clinical effect. Methods: A series of twenty women with initial diagnosis of ovarian cancer undergoing primary cytoreduction with tumor ablation involving the liver were compared to twenty women with initial diagnosis of ovarian cancer undergoing primary cytoreduction and tumor ablation without involvement of the liver. The data were compared with Fisher’s exact, Chi-square or Mann-Whitney U as appropriate. Results: Women undergoing tumor ablation involving the liver compared with women undergoing tumor ablation not involving the liver had significantly elevated AST and ALT levels the first day after surgery (p = 0.002; 0.002, respectively). There were no significant differences in age, operative blood loss or need for transfusion (p=0.24; 0.065; 0.33, respectively). The mean time for resolution of the elevations of AST and ALT was 2.5 days (95% CI = 1.8-3.2) for AST and 2.8 days (95% CI = 2.0 -3.6) for ALT. Conclusions:Significant elevations in AST and ALT occur when tumor involving the liver is ablated in women undergoing debulking for ovarian cancer. This elevation does not appear to increase operative blood loss or need for transfusion.
APA, Harvard, Vancouver, ISO, and other styles
8

Richardson, G. D., and B. Driver. "Ovarian vein ablation: coils or surgery?" Phlebology: The Journal of Venous Disease 21, no. 1 (2006): 16–23. http://dx.doi.org/10.1258/026835506775971135.

Full text
Abstract:
Objective: The aim of this study is to compare the results, namely improvement in pelvic pain and overall satisfaction with treatment by surgery, or by coils and sclerotherapy, for pelvic congestion syndrome (PCS) when caused by ovarian vein incompetence based on ultrasound assessment. To do so requires a brief description of the diagnosis of PCS and ovarian vein incompetence, and a discussion of the indications for treatment. Methods: The same questionnaire as used for a previous surgical series in 1989–95 was used for the present study. Independent assessment of responses to the questionnaire using visual analogue scales, together with review of the clinical notes, enabled statistical evaluation of two treatment groups. Treatment was by surgery from 1989 to 1998, and by coils and sclerotherapy from January 1999 to June 2002. Obtaining demographic and presenting symptom data has enabled us to compare the two groups, as well as the results of the two treatments. Results: There was no significant difference between the demographics and presenting symptoms of surgical and coil treatment groups. Surgical and coil groups combined show a statistically significant reduction in perceived pelvic pain, and overall satisfaction with treatment. There is no difference in reduction of perceived pelvic pain or in overall satisfaction between surgical and coil treatment groups. Conclusion: Treatment based on ultrasound diagnosis is justified. Surgical ovarian vein ablation should not be considered as having been superseded by coils. The latter has some advantages but also cost implications. Long-term success of coil treatment has not yet been proven. Recanalization of the ovarian vein, if it occurs, can be treated by further coils or surgery.
APA, Harvard, Vancouver, ISO, and other styles
9

Oseledchyk, Anton, Mary Gemignani, Maura N. Dickler, et al. "Surgical ovarian ablation for hormone receptor positive primary breast cancer in premenopausal women." Journal of Clinical Oncology 35, no. 15_suppl (2017): e12536-e12536. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12536.

Full text
Abstract:
e12536 Background: Ovarian ablation is increasingly used to complement endocrine therapy in select premenopausal women with hormone-receptor positive (HR+) breast cancer (BC). It can be achieved by either medical ovarian suppression (OS) or therapeutic bilateral salpingo-oophorectomy (BSO). We sought to investigate trends of therapeutic BSO in premenopausal patients at our institution. Methods: Premenopausal women with HR+ primary BC diagnosed from 2010-2014 were identified in our prospectively maintained BC database. Patients with confirmed BRCA1/2 mutations were excluded. Distribution of patient and disease characteristics between treatment groups were assessed using univariate logistic regression analyses. Surgical details and complications were extracted from our surgical database. Results: We identified 2,854 eligible patients; 2,113 (74%) received endocrine therapy without ovarian ablation, 246 (9%) received endocrine therapy plus medical OS, 180 (6%) underwent additional BSO, and 315 (11%) did not receive endocrine therapy at the time of analysis. Independent predictors for undergoing ovarian ablation were younger age (OR 0.98; 95%CI, 0.96-0.99; p < 0.001), higher grade (grade 3 vs 1: OR 3.17; 95%CI, 1.70-5.90; grade 2 vs 1: OR 3.13; 95%CI, 1.64-5.95; p < 0.001), lymph node involvement (OR 1.46; 95%CI, 1.19-1.80; p < 0.001), and higher AJCC stage as well as de novo metastatic BC (II vs I: OR = 1.35; 95%CI, 1.03-1.76; III vs I: OR 2.57; 95%CI, 1.86-3.55; IV vs I: OR 19.69; 95%CI, 12.76-30.39; p < 0.001). Among patients who underwent ovarian ablation, patients of younger age (1.04; 95%CI, 1.01-1.07; p = 0.009) and with metastatic BC (stage IV vs I: OR 0.36; 95%CI, 0.20-0.68; p = 0.007) were less likely to undergo BSO than OS. In 180 patients undergoing BSO, five adverse events were noted: two grade 1, two grade 2, and one grade 3 complication. Conclusions: Premenopausal women with HR+ BC with high-risk features or metastatic disease were more likely to undergo ovarian ablation at our institution. Surgical ovarian ablation is a safe alternative, with low complication rates. Understanding patient preferences, side effects, and quality of life implications will help guide personalized treatment decisions.
APA, Harvard, Vancouver, ISO, and other styles
10

Stewart, H. J. "Ovarian ablation - the last 100 years." Endocrine Related Cancer 4, no. 3 (1997): 223–27. http://dx.doi.org/10.1677/erc.0.0040223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Ovarian ablation"

1

Chamberlain, George W. Comparison of unilateral eyestalk ablation with environmental control for ovarian maturation of Penaeus stylirostris. Sea Grant College Program, Texas A & M University, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Juri Moran, Joulia Marianita, Paulina Elizabeth Durán Mora, Estefania Vanessa Arauz Andrade, et al. Ginecología Obstetricia: Patologías durante el embarazo. Mawil Publicaciones de Ecuador, 2019, 2020. http://dx.doi.org/10.26820/978-9942-826-07-7.

Full text
Abstract:
En Medicina, el área de aplicación de Ginecología, la ciencia de la mujer condensa el estudio de las enfermedades frecuentes y graves, el diagnóstico, detección de los factores de riesgo y establecer mecanismos de prevención, prescribir los tratamientos médicos y quirúrgicos de las enfermedades del sis- tema reproductor femenino, entiéndase, todo lo relacionado con la vagina, las mamas, el útero y los ovarios. Durante el siglo XX, motivado por el crecimiento acelerado del conocimien- to científico y médico, se acrecienta la toma de conciencia del rol que le co- rresponde desempeñar a la medicina en el sector de la salud y la protección de la mujer embarazada. Los problemas del trato genital femenino cuando se asumen como responsabilidad de los ginecólogos, quienes incluyeron dentro del proceso de auscultación, diagnóstico y tratamiento aspectos fisiológicos y endocrinos. Las barreras de la formación académica se fueron difuminando y los ginecó- logos y obstetras comenzaron a estrechar su campo laboral y como resultante se constituyó la Ginecobstetricia. En el marco de estas reflexiones, surge la idea de la presentación de un tex- to titulado Ginecología – Obstetricia, mediante el cual se pretende hacer una contribución real a nivel teórico que permita apoyar a profesionales y estu- diantes en el área de salud humana, básicamente en algunas de las patologías o complicaciones médicas asociadas al embarazo, y tratadas por la especialidad obstétrica, así mismo, se abordan dos temas (1 y 2) de conocimiento general. Cabe indicar que el texto no pretende abordar la vasta información o literatura que sobre los temas se han tratado. El libro ha sido estructurado bajo el perfil de diez (10) temas que discurren estrictamente sobre contenidos específicos, a sa- ber: 1. El parto y sus fases, 2. Pruebas de Bienestar Fetal, 3. Amenaza de Parto Pretérmino, 4. Ruptura Prematura de Membranas, 5. Amenaza de aborto, 6. Desprendimiento de placenta, 7. Infecciones de vías urinarias en embarazadas, 8. Diabetes Gestacional, 9. Hipertension en las embarazadas y 10. Preeclamp- sia y eclampsia En el primer tema, el Parto y sus fases, se precisan diferentes nociones sobre 26 GINECOLOGIA - OBSTETRICIA el proceso y el resultado de parir (dar a luz). A lo largo de la historia ha evolu- cionado el conocimiento de este tema dando como resultado una terminología precisa sobre los diferentes tipos de parto: parto natural, parto normal, parto ins- trumental, parto pretérmino, parto humanizado, etc. Estas nociones obedecen a determinadas circunstancias específicas que lo circunscribe como el uso o no de instrumentos que ayuden al nacimiento de un feto. De manera general, el parto marca el final del embarazo y el nacimiento de la criatura que se engendraba en el útero de la madre. Este proceso por el que la mujer o la hembra de una especie vivípara expulsa el feto y la placenta al final de la gestación consta de tres fases: la fase de dilatación, la de expulsión y la placentaria o de alumbramiento. En el segundo tema titulado Pruebas de Bienestar Fetal, se destaca el desa- rrollo de diferentes pruebas para el control del bienestar fetal. Éstas constitu- yen las técnicas aplicadas a las madres que permiten predecir el posible riesgo fetal o hacer un pronóstico del estado actual del feto, es decir, que tratan de conseguir a través de una valoración del feto de forma sistemática, la identifi- cación de aquellos que están en peligro dentro del útero materno, para así to- mar las medidas apropiadas y prevenir un daño irreversible. Se abordan en este contexto las indicaciones y los métodos (clínicos, biofísicos y bioquímicos más utilizados para el control de bienestar fetal. En el tema tres (3) denominado Amenaza de Parto Pretérmino, el trabajo se centra, en el desarrollo de los siguientes ítems. La Definición de Parto Pretérmi- no, la Definición de amenaza de Parto Pretérmino, la Evaluación del riesgo, la etiología, la Clínica de la Amenaza de Parto Pretérmino, el Diagnóstico precoz de la Amenaza de Parto Pretérmino, la Evaluación de gestantes que acuden a emergencia por signos y síntomas de Amenaza de Parto Pretérmino y el trata- miento. El trabajo parte de la definición de Parto Pretérmino entendido como aquel que ocurre después de la semana 23 y antes de la semana 37 de gestación, para posteriormente, tratar lo relativo a la Amenaza de Parto Pretérmino (APP) definido como el proceso clínico sintomático (Aparición de dinámica uterina regular acompañado de modificaciones cervicales) que puede conducir a un parto pretérmino. Su etiología es compleja y multifactorial, en la que pueden intervenir de forma simultánea factores inflamatorios, isquémicos, inmunológi- cos, mecánicos y hormonales. 27 GINECOLOGIA - OBSTETRICIA Por otro parte, el tema cuatro (4) expone la Ruptura Prematura de Membra- nas, la cual constituye una complicación usual en la práctica obstétrica, esta puede aumentar la incidencia en la morbilidad y mortalidad materna – fetal. Múltiples estudios se están llevando a cabo para poder dilucidar completamente su fisiopatología, lo cual se hace cada vez más necesario para poder aplicar estos conceptos en la práctica clínica, la evidencia actual indica que la Ruptura Prematura de Membrana es un proceso que puede ser afectado por factores: bioquímicos, fisiológicos, patológicos y ambientales. El capítulo cinco (5) comprende la temática sobre la Amenaza de aborto. (AA) que es la complicación más común durante el embarazo, se define como el sangrado transvaginal antes de las 20 semanas de gestación (SDG) gestación o con un feto menor de 500g, con o sin contracciones uterinas, sin dilatación cervical y sin expulsión de productos de la concepción”. Es decir, se presenta hemorragia de origen intrauterino antes de la vigésima semana completa de ges- tación, con o sin contracciones uterinas, sin dilatación cervical y sin expulsión de los productos de la concepción. Los síntomas abarcan amenorrea secundaria, presencia de vitalidad fetal y cólica abdominales con o sin sangrado vaginal entre otros. Para el diagnóstico se puede hacer una ecografía abdominal o va- ginal, examen pélvico y de laboratorio. En un principio el tratamiento consiste en recomendar reposo en cama y reposo pélvico. La identificación de factores de riesgo, el Ultrasonido obstétrico y la medición de marcadores bioquímicos son de gran importancia para realizar un diagnóstico y establecer un pronóstico oportuno. Estos aspectos y otros relacionados con el tema como son: la clínica, el protocolo a seguir, el tratamiento y la prevención, son tratados en este capí- tulo. El tema Desprendimiento de placenta es desarrollado a lo largo del tema seis (6). Su contenido aborda los aspectos importes como los factores de riesgo, etiología, síntomas y signos, diagnóstico y tratamiento de esta complicación cuyo proceso se caracteriza por el desprendimiento total o parcial, antes del parto, de una placenta que esta insertada en su sitio normal. Este hecho que puede traer grandes consecuencias para el feto y para la madre, puede ocurrir en cualquier momento del embarazo. Los desprendimientos producidos antes de las 20 semanas, por su evolución, deberán ser tratados como abortos. Los que tienen lugar después de la semana 20 de gestación y antes del alumbramiento constituyen el cuadro conocido como desprendimiento prematuro de la placenta normalmente insertada. (abrptio plantae o accidente de Baudelocque). El pro- ceso ha tenido una variedad de denominaciones a lo largo del tiempo y son consecuencia de la diversidad de cuadros clínicos que pueden producirse, sien- do las más empleadas en la actualidad: abruptio placentae, ablatio placentae, desprendimiento prematuro de placenta normalmente inserta (DPPNI), junto con el término abreviado desprendimiento prematuro de placenta (DPP). Para hablar de otra importante complicación que aqueja a la gestante y su bebe por nacer se expone en el tema (7) relacionado con las Infecciones de vías urinarias en embarazadas. Los particulares cambios morfológicos y funcio- nales que se producen en el tracto urinario de la gestante hacen que la infec- ción del tracto urinario (ITU) sea la segunda patología médica más frecuente del embarazo, por detrás de la anemia. Las 3 entidades de mayor repercusión son: Bacteriuria asintomática (BA) (2-11%), cuya detección y tratamiento son fundamentales durante la gestación, pues se asocia a prematuridad, bajo peso y elevado riesgo de progresión a pielonefritis aguda (PA) y sepsis; la Cistitis aguda (CA) (1,5%) y la Pielonefritis aguda (1-2%), principal causa de ingreso no obstétrico en la gestante, que en el 10 al 20% de los casos supone alguna complicación grave que pone en riesgo la vida materna y la fetal. La Diabetes Gestacional se ubica y desarrolla en el tema ocho (8). Este tipo de diabetes que aparece o se diagnostica durante el embarazo ha aumentado su prevalencia y cobrado gran relevancia epidemiológica en los últimos años. La Diabetes Gestacional (DG) o Diabetes Mellitius Gestacional (DMG) se carac- teriza por una secreción de insulina insuficiente para compensar la resistencia a la hormona, propia del embarazo. Después del parto, los niveles de glucosa sanguínea suelen normalizarse; sin embargo, algunas mujeres desarrollan DM tipo 2 y se asocia con complicaciones graves en la madre y el hijo, incluso años después del nacimiento. La Hipertensión en las Embarazadas, tema tan tratado y controvertido en los últimos años por su significación a nivel de que es la complicación médica 29 GINECOLOGIA - OBSTETRICIA más frecuente de la gestación y ocurre según estudios comprobados en el 7% a 10% de los embarazos y constituye una causa importante de morbimortalidad materna y perinatal. De manera clásica, la HTA en el embarazo ha sido definida como el incremento, durante la gestación, de la presión arterial sistólica (PAS) en 30 mmHg o más y/o la presión arterial diastólica (PAD) en 15 mmHg o más comparado con el promedio de valores previos a la 20va. semana de gestación. Cuando no se conocen valores previos, una lectura de 140/90 mmHg o mayor es considerada como anormal. El tema desarrollado abarca una visión general sobre algunos aspectos relativos a la definición y su clasificación, los factores predisponentes, sintomatología, diagnóstico, tratamiento, etc. Por último, el tema 10 aborda dos alteraciones íntimamente ligadas a la hi- pertensión arterial en el embarazo: la preeclampsia y la eclampsia. Éstas son en ocasiones tratadas como componentes de un mismo síndrome ya que la pree- clampsia es la hipertensión de reciente comienzo con proteinuria después de las 20 semanas de gestación y la eclampsia es la presencia de convulsiones genera- lizadas inexplicables en pacientes con preeclampsia.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Ovarian ablation"

1

Pritchard, Kathleen I. "Ovarian ablation as adjuvant therapy for early-stage breast cancer." In Cancer Treatment and Research. Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-6189-7_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pritchard, K. I. "GnRH Analogues and Ovarian Ablation: Their Integration in the Adjuvant Strategy." In Recent Results in Cancer Research. Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-45769-2_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Butler-Manuel, Simon, Mario M. Leitao, and Yukio Sonoda. "Instrumentation, Retractors, Ablative Technologies and Techniques, Setup, and Conduct of Operation." In Surgery for Ovarian Cancer, 4th ed. CRC Press, 2022. http://dx.doi.org/10.1201/9780429054433-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pritchard, Kathleen. "Ovarian ablation." In Endocrine Management of Breast Cancer. CRC Press, 2002. http://dx.doi.org/10.1201/b14733-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Ovarian Ablation." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jones, Kellie L. "Chapter 2 Ovarian ablation." In Endocrine Therapies in Breast Cancer. Oxford University Press, 2007. http://dx.doi.org/10.1093/med/9780199218141.003.0002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Stewart, H. J., and D. Everington. "Ovarian Ablation versus CMF Chemotherapy as Adjuvant Therapy for Breast Cancer." In Contributions to Oncology. S. Karger AG, 1995. http://dx.doi.org/10.1159/000424685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schmitt, Isabell A., Milana Dolezal, and Michael F. Press. "Progression from Hormone-Dependent to Hormone-Independent Breast Cancer." In Hormones, Genes, And Cancer. Oxford University PressNew York, NY, 2003. http://dx.doi.org/10.1093/oso/9780195135763.003.0014.

Full text
Abstract:
Abstract Breast cancer is the most common malignancy in women, and treatment is challenging. The potential role of hormonal therapy in breast cancer treatment was first demonstrated by George Beatson more than 100 years ago, when he showed that two of three premenopausal women with metastatic breast cancer responded to ovarian ablation. Subsequently, Huggins and Bergenstal demonstrated that postmenopausal women with metastatic breast cancer responded to ovariectomy and adrenalectomy. Despite the usefulness of hormonal ablation in some women, only approximately 30% of unselected women with metastatic breast cancer responded to the treatment. Thus, there was a need to distinguish those women whose breast cancers were hormone-dependent from those whose cancers were hormone-independent. Jensen and collaborators demonstrated that patient responsiveness to endocrine manipulative management was correlated with the uptake of estrogen in the breast cancer tissue. The first results showed that uptake of radioactive hormone was higher in breast cancer tissue compared to muscle tissue from four women who responded to hormonal treatment than from six women who did not respond. These findings were soon confirmed and extended by reports from other investigators.5–8
APA, Harvard, Vancouver, ISO, and other styles
9

BURNS, KATHLEEN H., and MARTIN M. MATZUK. "The Application of Gene Ablation and Related Technologies to the Study of Ovarian Function." In The Ovary. Elsevier, 2004. http://dx.doi.org/10.1016/b978-012444562-8/50024-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

O. Amarin, Zouhair, and Omar F. Altal. "Alternatives to Hysterectomy for Dysfunctional Uterine Bleeding." In Hysterectomy Matters [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.113758.

Full text
Abstract:
Hysterectomy is a major surgical procedure that is performed through conventional laparotomy, laparoscopy and robotic surgery, or through the vaginal route to avoid abdominal wall incisions. In certain situations, both the abdominal and vaginal routes are used in combination. Hysterectomy is indicated for malignancies of the uterus, uterine cervix, and ovaries; to reduce the risk of future malignancies and genital prolapse; and for dysfunctional uterine bleeding. Dysfunctional uterine bleeding is an aberration caused by hormonal imbalance that is not related to the normal menstrual cycle, with no clear etiology in most cases. Dysfunctional uterine bleeding can be treated medically or surgically. Medical treatment includes non-steroidal anti-inflammatory drugs, the combined oral contraceptive pills, progestogens, danazol, analogs of gonadotrophin-releasing hormone, and the anti-fibrinolytic tranexamic acid. Endometrial ablation and hysterectomy are common routine, low-risk surgical procedures for dysfunctional uterine bleeding but are associated with some comparatively rare serious complications, both operatively and post-operatively. All types of endometrial ablation and hysterectomy remain a mainstay of alternative options for patients where the medical approach proves to be ineffective or is associated with intolerable side effects.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ovarian ablation"

1

Bese, NS, A. Iribas, DC Oksuz, G. Atkovar, and A. Ober. "Ovarian ablation by radiotherapy; is it still an option for the ovarian function suppression in endocrine responsive premenopausal breast cancer patients?." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-5137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Xu, Junnnan, and Tao Sun. "Abstract PS9-48: Depression, sexual dysfunction and quality of life among breast cancer patients with ovarian function suppression: A cross sectional study between ovarian ablation verse GnRH agonists." In Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ps9-48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rodrigues, Alana Santos, Camilly Lorrane Prates de Azevedo, Emanuele Prado Martins, et al. "Gynecology and obstetrics: Impacts of endometriosis on female fertility." In IV Seven International Congress of Health. Seven Congress, 2024. http://dx.doi.org/10.56238/homeivsevenhealth-058.

Full text
Abstract:
Introduction: Endometriosis is a chronic inflammatory pathology caused by the appearance of fragments ofendometrial tissue outside the uterine cavity, which affects women of reproductive age. This condition can present with a wide variety of clinical manifestations, causing severe pelvic pain, symptoms resulting from injury to non-reproductive organs, and infertility. Studies indicate that about 30 to 50% of infertile women have endometriosis, thus suggesting a possible contribution of endometriosis in the etiopathogenesis of infertility. Therefore, in order to treat endometriosis and promote the patient's fertility, clinical and surgical treatments can be offered. Objective: This project aims to carry out a literature analysis about endometriosis and its impacts on female fertility, as well as the treatment of this condition. Methodology: this is an integrative review of the literature, carried out in the following databases: Scientific Electronic Library Online (SciELO), Web of Science and National Library of Medicine (PubMed/Medline), Google Scholar and Virtual Health Library (VHL). A total of 50 publications were identified, and 30 bibliographic references from the last 22 years were used. The exclusion criteria were non-pertinence to the theme, and articles prior to this period. The articles analyzed were selected according to the descriptors: endometriosis, infertility and reproduction. Results: considering that endometriosis is related to infertility, measures are necessary to treat this condition, for this, ablation of the lesions associated with adsiolysis, expectant management or ovarian stimulation associated with intrauterine insemination or FIVETE can be considered. Conclusion: considering that endometriosis can lead to infertility, it is of paramount importance to carry out the early diagnosis of the disease, enabling the effectiveness of the treatment of the condition and promotion of the woman's fertility
APA, Harvard, Vancouver, ISO, and other styles
4

Macchia, Gabriella, Maura Campitelli, Donato Pezzulla, et al. "PT006/#314 Stereotactic ablative radiotherapy for oligometastatic ovarian cancer lymph node disease: the MITO-RT3/rad phase II trial." In IGCS 2024 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/ijgc-2024-igcs.29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kim, Yong Bae, Chan Woo Wee, Hojin Kim, et al. "Standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a prospective randomized phase III trial (KGOG 3064/KROG 2204)." In The 39th Annual Meeting of the Korean Society of Gynecologic Oncology. Korean Society of Gynecologic Oncology, 2024. http://dx.doi.org/10.3802/jgo.2024.35.s2.p26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Woo Wee, Chan, So-Jin Shin, Jae Hong No, et al. "TP024/#1560 Standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a prospective randomized phase III trial (KGOG 3064/KROG 2204)." In IGCS 2023 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/ijgc-2023-igcs.484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kim, Yong Bae, Hwa Kyung Byun, Jung-Yun Lee, et al. "TP029/#1459 Prospective multi-institutional phase III trial of standard of care therapy with or without sterotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC, KGOG 3064/KROG 2204)." In IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.538.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ovarian ablation' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography